Kite Pharma Reaches Analyst Target Price. In recent trading, shares of Kite Pharma Inc (Symbol: KITE) have crossed above the average analyst 12-month target price of $70.82, changing hands for $79.62/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.